ArticleJournal of diabetes investigation2022

Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.

Eiichi Araki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.